Wellington Management Group LLP Takes Position in Vor Biopharma Inc. $VOR

Wellington Management Group LLP bought a new position in shares of Vor Biopharma Inc. (NASDAQ:VOR) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 27,100 shares of the company’s stock, valued at approximately $499,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new position in Vor Biopharma during the second quarter worth $66,000. Susquehanna Portfolio Strategies LLC purchased a new position in Vor Biopharma during the fourth quarter valued at $134,000. Jane Street Group LLC purchased a new position in Vor Biopharma during the first quarter valued at $140,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Vor Biopharma in the fourth quarter valued at about $141,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Down 0.2%

Shares of VOR opened at $22.30 on Friday. Vor Biopharma Inc. has a 52-week low of $6.50 and a 52-week high of $49.95. The firm’s fifty day moving average is $21.71 and its two-hundred day moving average is $17.44.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, analysts forecast that Vor Biopharma Inc. will post -2.56 EPS for the current year.

Wall Street Analyst Weigh In

VOR has been the subject of a number of research reports. Wall Street Zen raised shares of Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a report on Monday, May 18th. Wedbush boosted their price objective on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings upgraded Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.38.

Vor Biopharma Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor’s lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.